Literature DB >> 15485822

Toll-like receptor 9 regulates tumor necrosis factor-alpha expression by different mechanisms. Implications for osteoclastogenesis.

Alla Amcheslavsky1, Wei Zou, Zvi Bar-Shavit.   

Abstract

CpG oligodeoxynucleotides (CpG-ODNs), mimicking bacterial DNA, stimulate osteoclastogenesis via Toll-like receptor 9 (TLR9) in receptor activator of NF-kappa B ligand (RANKL)-primed osteoclast precursors. This activity is mediated via tumor necrosis factor (TNF)-alpha induction by CpG-ODN. To further reveal the role of the cytokine in TLR9-mediated osteoclastogenesis, we compared the ability of CpG-ODN to induce osteoclastogenesis in two murine strains, BALB/c and C57BL/6, expressing different TNF-alpha alleles. The induction of osteoclastogenesis and TNF-alpha release by CpG-ODN was by far more noticeable in BALB/c-derived than in C57BL/6-derived osteoclast precursors. Unexpectedly, as revealed by Northern analysis, CpG-ODN induction of TNF-alpha mRNA increase was more efficient in C57BL/6-derived cells. The cytokine transcript abundance was increased due to both increased message stability and rate of transcription. The difference between the two cell types was the result of a higher transcription rate in CpG-ODN-induced C57BL/6-derived cells caused by a single nucleotide polymorphism in kappa B2a site within the TNF-alpha promoter sequence. CpG-ODN enhanced the rate of the cytokine translation in BALB/c-derived cells. Thus, CpG-ODN modulated both transcription and translation of TNF-alpha. The induction of transcription was more evident in C57BL/6-derived cells, while the induction of translation took place only in BALB/c-derived osteoclast precursors. Altogether the cytokine was induced to a larger extent in BALB/c-derived osteoclast precursors, consistent with the increased CpG-ODN osteoclastogenic effect in these cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15485822     DOI: 10.1074/jbc.M409138200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

Review 1.  Hypothesis-driven candidate gene association studies: practical design and analytical considerations.

Authors:  Timothy J Jorgensen; Ingo Ruczinski; Bailey Kessing; Michael W Smith; Yin Yao Shugart; Anthony J Alberg
Journal:  Am J Epidemiol       Date:  2009-09-17       Impact factor: 4.897

2.  Rutin inhibits osteoclast formation by decreasing reactive oxygen species and TNF-alpha by inhibiting activation of NF-kappaB.

Authors:  Tae Wook Kyung; Ji Eun Lee; Hyun Hee Shin; Hye Seon Choi
Journal:  Exp Mol Med       Date:  2008-02-29       Impact factor: 8.718

3.  An oligodeoxynucleotide with promising modulation activity for the proliferation and activation of osteoblast.

Authors:  Zhiyuan Feng; Yuqin Shen; Liying Wang; Lin Cheng; Jing Wang; Quanshun Li; Wei Shi; Xinhua Sun
Journal:  Int J Mol Sci       Date:  2011-04-15       Impact factor: 5.923

4.  An oligodeoxynucleotide that induces differentiation of bone marrow mesenchymal stem cells to osteoblasts in vitro and reduces alveolar bone loss in rats with periodontitis.

Authors:  Yuqin Shen; Zhiyuan Feng; Chongtao Lin; Xu Hou; Xueju Wang; Jing Wang; Yongli Yu; Liying Wang; Xinhua Sun
Journal:  Int J Mol Sci       Date:  2012-03-05       Impact factor: 6.208

5.  Broad-spectrum drugs against viral agents.

Authors:  Mary E Christopher; Jonathan P Wong
Journal:  Int J Mol Sci       Date:  2008-09-01       Impact factor: 6.208

6.  The Toll-like receptor ligand, CpG oligodeoxynucleotides, regulate proliferation and osteogenic differentiation of osteoblast.

Authors:  Wenwen Yu; Yi Zheng; Hongyan Li; Hongbing Lin; Zhen Chen; Yue Tian; Huishan Chen; Peipei Zhang; Xiaowei Xu; Yuqin Shen
Journal:  J Orthop Surg Res       Date:  2020-08-14       Impact factor: 2.359

7.  A Squalene-Based Nanoemulsion for Therapeutic Delivery of Resiquimod.

Authors:  Zhongkun Zhang; Jimmy Chun-Tien Kuo; Chi Zhang; Yirui Huang; Zerui Zhou; Robert J Lee
Journal:  Pharmaceutics       Date:  2021-12-02       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.